Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Flexion Therapeutics Inc (NASDAQ:FLXN)

24.28
Delayed Data
As of Oct 18
 -1.09 / -4.30%
Today’s Change
15.93
Today|||52-Week Range
32.25
+27.66%
Year-to-Date
Playing Biotech After FDA Approval
Oct 16 / TheStreet.com - Paid Partner Content
Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher
Oct 09 / Zacks.com - Paid Partner Content
Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up
Oct 09 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close25.37
Today’s open25.29
Day’s range24.15 - 25.52
Volume2,256,438
Average volume (3 months)1,000,016
Market cap$931.2M
Dividend yield--
Data as of 3:59pm ET, 10/18/2017

Growth & Valuation

Earnings growth (last year)-32.09%
Earnings growth (this year)-32.79%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book4.30

Competitors

 Today’s
change
Today’s
% change
ENTAEnanta Pharmaceutica...-0.45-0.94%
SPPISpectrum Pharmaceuti...+5.21+36.03%
EGRXEagle Pharmaceutical...-0.06-0.12%
ITCIIntra-Cellular Thera...+0.03+0.19%
Data as of 4:00pm ET, 10/18/2017

Financials

Next reporting dateNovember 15, 2017
EPS forecast (this quarter)-$0.95
Annual revenue (last year)$0.00
Annual profit (last year)-$71.9M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer, CFO &
Director
Michael D. Clayman
Chief Scientific Officer
Neil Bodick
Corporate headquarters
Burlington, Massachusetts

Forecasts